Quinazoline derivatives bearing an adamantyl group at the aniline ring were identified as potential EGFR inhibitors.
Several analogues exhibited higher anti-tumor potency than gefitinib.
Compound 3d displayed moderate activity against H1975 cells harboring the EGFRT790M mutation.